Proportions of several types of plasma and urine microparticles are increased in patients with rheumatoid arthritis with active disease

• Published in: Clinical and experimental immunology 2015-06, Vol.180 (3), p.442-451
• Main Authors: Viñuela‐Berni, V., Doníz‐Padilla, L., Figueroa‐Vega, N., Portillo‐Salazar, H., Abud‐Mendoza, C., Baranda, L., González‐Amaro, R.
• Format: Article
• Language: English
• Subjects: Adult; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - immunology; Arthritis, Rheumatoid - metabolism; Arthritis, Rheumatoid - urine; Biomarkers - metabolism; Case-Control Studies; Cell-Derived Microparticles - immunology; Cell-Derived Microparticles - metabolism; Cytokines - biosynthesis; Cytokines - blood; Female; Humans; immune cells; Immunophenotyping; Immunosuppressive Agents - pharmacology; Immunosuppressive Agents - therapeutic use; immunosuppressive therapy; Leukocytes, Mononuclear - immunology; Leukocytes, Mononuclear - metabolism; Male; microparticles; Middle Aged; Phenotype; rheumatoid arthritis; Translation; Young Adult
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1111/cei.12598

Summary We analysed the proportions of different microparticles (MPs) in plasma from patients with rheumatoid arthritis (RA), and assessed their relationship with disease activity/therapy and their in‐vitro effect on proinflammatory cytokine release. Blood and urine samples were obtained from 55 patients with RA (24 untreated and 31 under conventional therapy) and 20 healthy subjects. Fourteen patients with systemic lupus erythematosus (SLE) were also studied. The proportions of CD3+, CD14+, CD19+, CD41+ and CD62E+ MPs were determined by flow cytometry analysis. The in‐vitro effect of plasma MPs on the release of interleukin (IL)‐1, IL‐6, IL‐17 and tumour necrosis factor (TNF)‐α was also analysed. We detected that the proportions of different types of annexin‐V+ MPs were enhanced in plasma (CD3+, CD14+, CD19+, CD41+ and CD62E+ MPs) and urine (CD14+, CD3+ and CD19+ MPs) from RA patients with high disease activity (DAS28 index > 5·1). Accordingly, a significant positive correlation was observed between the levels of MPs and DAS28 score, and these levels diminished significantly at week 4 of immunosuppressive therapy. Finally, MPs isolated from patients with high disease activity induced, in vitro, an enhanced release of IL‐1, IL‐17 and TNF‐α. In SLE, enhanced levels of different types of plasma MPs were also detected, with a tight correlation with disease activity. Our data further support that MPs have a relevant role in the pathogenesis of RA and suggest that the analysis of the proportions of these microvesicles in plasma could be useful to monitor disease activity and therapy response in patients with RA.